HLA-Haploidentical Stem Cell Transplantation for Hematologic Malignancies

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages S57-S63

  Fuchs, Ephraim J ^a   Huang, Xiao jun ^b   Miller, Jeffrey S ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adoptive immunotherapy; Graft versus host disease; Human leukocyte antigens; Natural killer cells; Stem cell transplantation; Transplantation conditioning

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LEUKOCYTE ANTIGEN; HLA ANTIGEN;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ARTICLE; DONOR SELECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOLOGICAL TOLERANCE; MORTALITY; NATURAL KILLER CELL; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; POST TREATMENT SURVIVAL; PROTEIN INTERACTION; RELAPSE; BLOOD DISEASE; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; REVIEW; TRANSPLANTATION;

HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; TRANSPLANTATION CONDITIONING;

EID: 77953074172     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.032     Document Type: Article

References (42)

1. Szydlo, R., Goldman, J.M., Klein, J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15 (1997), 1767–1777.
2. Drobyski, W.R., Klein, J., Flomenberg, N., et al. Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99 (2002), 806–814.
3. Eapen, M., Rubinstein, P., Zhang, M.J., et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 369 (2007), 1947–1954.
4. Barker, J.N., Weisdorf, D.J., Defor, T.E., et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105 (2005), 1343–1347.
5. Brunstein, C.G., Barker, J.N., Weisdorf, D.J., et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 110 (2007), 3064–3070.
6. Beatty, P.G., Clift, R.A., Mickelson, E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313 (1985), 765–771.
7. Anasetti, C., Amos, D., Beatty, P.G., et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 320 (1989), 197–204.
8. Anasetti, C., Beatty, P.G., Storb, R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 29 (1990), 79–91.
9. O'Reilly, R.J., Keever, C., Kernan, N.A., et al. HLA nonidentical T cell depleted marrow transplants: a comparison of results in patients treated for leukemia and severe combined immunodeficiency disease. Transplant Proc 19:Suppl 7 (1987), 55–60.
10. Bethge, W.A., Faul, C., User, M., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: An update. Blood Cells Mol Dis 40 (2008), 13–19.
11. Rizzieri, D.A., Koh, L.P., Long, G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 25 (2007), 690–697.
12. Federmann, B., Bornhauser, M., Beelen, D.W., et al. Haploidentical allogeneic hematopoietic cell transplantation in adults using reduced intensity conditioning and CD3/CD19-depleted grafts: interim analysis of a phase I/II study. ASH Annu Meet Abstr, 112, 2008, 1962.
13. Luznik, L., O'Donnell, P.V., Symons, H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14 (2008), 641–650.
14. Burroughs, L.M., O'Donnell, P.V., Sandmaier, B.M., et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 14 (2008), 1279–1287.
15. Devetten, M.P., Hari, P.N., Carreras, J., et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 15 (2009), 109–117.
16. Kasamon, Y.L., Leffell, M.S., Kowalski, J., et al. Greater HLA disparity is associated with reduced risk of relapse and improved event-free survival after nonmyeloablative, HLA-haploidentical BMT with post-transplantation high-dose cyclophosphamide. ASH Annu Meet Abstr, 112, 2008, 150.
17. Kanda, Y., Chiba, S., Hirai, H., et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102 (2003), 1541–1547.
18. Ash, R.C., Horowitz, M.M., Gale, R.P., et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 7 (1991), 443–452.
19. Aversa, F., Tabilio, A., Velardi, A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 339 (1998), 1186–1193.
20. Aversa, F., Terenzi, A., Tabilio, A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005), 3447–3454.
21. Ruggeri, L., Capanni, M., Urbani, E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002), 2097–2100.
22. Huang, X.J., Han, W., Xu, L.P., et al. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease. Chin Med J 117 (2004), 1778–1785.
23. Huang, X.J., Liu, D.H., Liu, K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 38 (2006), 291–297.
24. Chang, Y.J., Lp, Xu, Liu, D.H., et al. Platelet engraftment in patients with hematologic malignancies following unmanipulated haploidentical blood and marrow transplantation: effects of CD34+ cell dose and disease status. Biol Blood Marrow Transplant 15 (2009), 632–638.
25. Liu, D., Huang, X., Liu, K., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transplant 14 (2008), 469–477.
26. Chen, S.H., Li, X., Huang, X.J., Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 79 (2004), 178–184.
27. Jun, H.X., Jun, C.Y., Yu, Z.X., In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 89 (2004), 1517–1524.
28. Huang, X.J., Liu, D.H., Liu, K.Y., et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant 15 (2009), 257–265.
29. Luo, X.H., Chang, Y.J., Xu, L.P., et al. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched//haploidentical hematopoietic SCT. Bone Marrow Transplant 43 (2008), 29–36.
30. Huang, X.J., Liu, D.H., Liu, K.Y., et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 28 (2008), 276–283.
31. Lu, D.P., Dong, L., Wu, T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107 (2006), 3065–3073.
32. Raulet, D.H., Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol 18 (2006), 145–150.
33. Yokoyama, W.M., Kim, S., Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev 214 (2006), 143–154.
34. Anfossi, N., Andre, P., Guia, S., et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006), 331–342.
35. Cooley, S., Xiao, F., Pitt, M., et al. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110 (2007), 578–586.
36. Miller, J.S., Soignier, Y., Panoskaltsis-Mortari, A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 105 (2005), 3051–3057.
37. Davies, S.M., Ruggieri, L., DeFor, T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 100 (2002), 3825–3827.
38. Farag, S.S., Bacigalupo, A., Eapen, M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 12 (2006), 876–884.
39. Miller, J.S., Cooley, S., Parham, P., et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 109 (2007), 5058–5061.
40. Giebel, S., Locatelli, F., Lamparelli, T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003), 814–819.
41. Cooley, S., McCullar, V., Wangen, R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106 (2005), 4370–4376.
42. Cooley, S., Trachtenberg, E., Bergemann, T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113 (2009), 726–732.